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Simple Summary: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetrybased radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin’s
lymphoma using the theranostic pair of 111 In and 90 Y anti-CD20 ibritumomab tiuxetan (Zevalin® ) at
myeloablative radiation-absorbed doses with autologous stem cell support. Unlike most routine dose
escalation approaches, our approach used patient-individualized measurements of organ radiation
absorbed dose from the tracer study, with patient-specific adjustments of the injected therapy dose
to deliver a pre-specified radiation absorbed dose to the liver. Our approach was feasible, stem cell
engraftment was swift, resulted in an 89% tumor response rate in treated patients, demonstrated
over 3 fold variability in liver dosimetry/injected activity among patients, allowed us to exceed the
FDA approved administered activity by over 5 fold and demonstrated the normal liver maximum
tolerated dose to exceed 28 Gy. Dose escalation was not continued due to lack of drug availability.
With modern dosimetry approaches, patient specific dosimetry-driven radiation dose escalation is
feasible, allows adjustment of administered activity for heterogeneous pharmacokinetics and allows
marked dose escalation vs. non-dosimetry driven approaches.
Abstract: Purpose: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetrybased radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin’s
lymphoma using the theranostic pair of 111 In and 90 Y anti-CD20 ibritumomab tiuxetan (Zevalin® ) at
myeloablative radiation-absorbed doses with autologous stem cell support. We also assessed acute
non-hematopoietic toxicity and early tumor response in this two-center outpatient study. Methods:
24 patients with CD20-positive relapsed or refractory rituximab-sensitive, low-grade, mantle cell, or
diffuse large-cell NHL, with normal organ function, platelet counts > 75,000/mm3 , and <35% tumor
involvement in the marrow were treated with Rituximab (375 mg/m2 ) weekly for 4 consecutive
weeks, then one dose of cyclophosphamide 2.5 g/m2 with filgrastim 10 mcg/kg/day until stem cell
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collection. Of these, 18 patients with successful stem cell collection (at least 2 × 106 CD34 cells/kg)
proceeded to RIT. A dosimetric administration of 111 In ibritumomab tiuxetan (185 MBq) followed by
five sequential quantitative planar and one SPECT/CT scan was used to determine predicted organ
radiation-absorbed dose. Two weeks later, 90 Y ibritumomab tiuxetan was administered in an outpatient setting at a cohort- and patient-specific predicted organ radiation-absorbed dose guided by a
Continuous Response Assessment (CRM) methodology with the following cohorts for dose escalation:
14.8 MBq/kg, and targeted 18, 24, 28, and 30.5 Gy to the liver. Autologous stem cell infusion occurred
when the estimated marrow radiation-absorbed dose rate was predicted to be <1 cGy/h. Feasibility,
short-term toxicities, and tumor response were assessed. Results: Patient-specific hybrid SPECT/CT
+ planar organ dosimetry was feasible in all 18 cases and used to determine the patient-specific
therapeutic dose and guide dose escalation (26.8 ± 7.3 MBq/kg (mean), 26.3 MBq/kg (median) of
90 Y (range: 12.1–41.4 MBq/kg)) of ibritumomab tiuxetan that was required to deliver 10 Gy to the
liver. Infused stem cells engrafted rapidly. The most common treatment-related toxicities were
hematological and were reversible following stem cell infusion. No significant hepatotoxicity was
seen. One patient died from probable treatment-related causes—pneumonia at day 27 post-transplant.
One patient at dose level 18 Gy developed myelodysplastic syndrome (MDS), 4 patients required
admission post-90 Y RIT for febrile neutropenia, 16/18 patients receiving 90 Y ibritumomab tiuxetan
(89%) responded to the therapy, with 13 CR (72%) and 3/18 PR (17%), at 60 days post-treatment. Two
patients had progressive disease at sixty days. One patient was lost to follow-up. Median time to
progression was estimated to be at least 13 months. MTD to the liver is greater than 28 Gy, but the
MTD was not reached as the study was terminated due to unexpected discontinuation of availability
of the therapeutic agent. Conclusions: Patient-specific outpatient 90 Y ibritumomab tiuxetan RIT with
myeloablative doses of RIT up to a targeted 30.5 Gy to the liver is feasible, guided by prospective
SPECT/CT + planar imaging with the theranostic pair of 111 In and 90 Y anti-CD20, with outpatient
autologous stem cell transplant support. Administered activity over 5 times the standard FDAapproved activity was well-tolerated. The non-hematopoietic MTD in this study exceeds 28 Gy to
the liver. Initial tumor responses were common at all dose levels. This study supports the feasibility
of organ dosimetry-driven patient-specific dose escalation in the treatment of NHL with stem cell
transplant and provides additional information on the radiation tolerance of the normal liver to
radiopharmaceutical therapy.
Keywords: radioimmunotherapy; dosimetry; quantitative SPECT imaging; anti CD20; lymphoma;
theranostics

1. Introduction
Anti-CD20-targeted monoclonal antibodies, both unlabeled and radiolabeled, are
active agents in the treatment of B-cell lymphomas [1,2]. The addition of radioactivity to
the anti-CD20 antibody increases therapeutic efficacy over the unlabeled antibody [3,4]. The
FDA has approved two anti-CD20 radio-immunotherapies for follicular lymphomas: 131 I
tositumomab plus unlabeled tositumomab (Bexxar® , Philadelphia, PA, USA) and rituximab
plus 90 Y ibritumomab tiuxetan (Zevalin® , East Windsor, NJ, USA). Their administered
radioactivity doses, and quite likely their efficacy, are limited by hematopoietic toxicity,
predominantly thrombocytopenia [5]. 131 I rituximab has similar efficacy and dose, limiting
hematopoietic toxicities [6]. While anti-CD20 radio-immunotherapies are effective and
safe, their utilization at non-myeloablative doses has been relatively limited given the
availability of other therapeutic approaches and other factors, with only 44 treatments
reported for Zevalin in a European therapy survey in 2015 [7,8]. Indeed, Bexxar is no longer
commercially available, mainly due to low commercial sales.
Lymphomas, particularly follicular lymphomas, are not generally cured with conventional therapies. Consolidative 131 I Bexxar radioimmunotherapy after conventional
chemotherapy has recently shown very promising outcomes [9]. Thus, there is renewed
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interest in the use of radioimmunotherapy and other approaches to improve outcomes of
patients with lymphoma.
Using modern SPECT/CT dosimetry approaches, baseline 131 I tositumomab dosimetry scans predict radiation dosimetry estimates on post-therapy scans. Dosimetry also
showed increased radiation-absorbed dose (>200 cGy) to lymphomas to be significantly
associated with longer progression-free survival [10]. Thus, there is strong evidence to
suggest that increasing tumor radiation-absorbed dose would enhance tumor response.
To substantially increase radiation-absorbed doses to tumors requires dose escalation
with stem cell transplant support to mitigate hematopoietic toxicities. 131 I tositumomab has
been used at myeloablative doses guided by planar dosimetry with stem cell transplants,
with encouraging results [11–13].
The radiation dosimetry profiles differ between 131 I tositumomab and 90 Y ibritumomab tiuxetan, with a substantially higher radiation-absorbed dose delivered to the
liver by 90 Y ibritumomab tiuxetan relative to 131 I tositumomab. This is likely because
radiometals such as indium and yttrium are retained in the liver to a greater extent than
radioiodine [14]. Wiseman et al. reported a median estimated radiation-absorbed dose of
3.4 Gy to liver (range 1.2–7.8 Gy), 2.6 Gy to lungs (range 0.72–4.4 Gy), and 0.38 Gy to kidneys
(range 0.07–0.61 Gy) for the standard dosing regimen [15]. Considerable patient-to-patient
variability in dosimetry to normal tissues has been seen with Zevalin radioimmunotherapy [15–17].
Given that the lungs, or much less commonly the kidneys, received the highest
radiation-absorbed dose with 131 I anti-CD20 therapy, while the liver received the highest
estimated radiation-absorbed dose in 90 Y ibritumomab therapies, the non-hematopoietic
toxicity of higher-dose 90 Y ibritumomab tiuxetan therapy with stem cell support might
be expected to be different than that of high-dose 131 I tositumomab. In addition, the
pure high-energy beta emission of 90 Y delivers the vast majority of its energy within the
patient without a gamma emission, a practical advantage vs. 131 I, which has a 364 keV
gamma emission, necessitating substantial radiation safety precautions, including inpatient
stays. Further, there is relatively little 90 Y excretion from the patient when 90 Y monoclonal
antibodies are administered, in contrast to the substantial urinary excretion with 131 I. Thus,
the radiation safety profile for higher-dose 90 Y myeloablative RIT with autologous stem
cell transplant support lends itself to outpatient therapy. The higher beta energy of 90 Y vs.
131 I is expected to deliver radiation more uniformly to large tumor foci, also a potential
advantage for RIT with 90 Y.
Two groups have reported on the use of myeloablative doses of Y-90 Ibritumomomab
Tiuxetan in the treatment of NHL. In both studies, dose escalations were based on escalating
mBq/kg dosing cohorts informed by planar dosimetry imaging methods, not including
SPECT/CT. Target liver radiation-absorbed doses were not to exceed 20 Gy [16]. Planar
imaging is not as accurate as SPECT/CT imaging, indeed there is considerable variability
among dosimetry approaches on the same datasets [16].
It is increasingly possible to perform accurate quantitative SPECT dosimetry with CTbased attenuation correction. One approach is to perform multiple SPECT/CT studies over
time [10]. Another approach is to ascertain the shape of the time-activity curve for an organ
from planar imaging and adjust its precise height using SPECT/CT performed at one or
more time points [18,19]. Prospectively performing organ dosimetry in individual patients
has technical and logistical challenges. In the present study, we sought to determine the
feasibility of such a real-time approach in patients with lymphoma to allow for substantial
prospective precision dose escalation.
Thus, we conducted a phase I dose escalation study of 90 Y ibritumomab tiuxetan using
111 In ibritumomab tiuxetan as a surrogate for 90 Y ibritumomab tiuxetan, for treatment
planning in patients with CD20-positive NHL, guided by more accurate organ-specific
dosimetry determined by hybrid SPECT/CT and planar imaging. The goals of our study
were to determine (a) the feasibility of SPECT/CT + planar prospective real-time dosimetry
for guiding individual patient administered radioactivity levels, (b) the feasibility of fully
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outpatient RIT with ASCT support, (c) to estimate the non-hematological MTD of this
treatment approach, especially as related to radiation-induced hepatotoxicity (up to 30.5 Gy)
and marrow re-engraftment, and (d) to preliminarily assess the therapeutic activity of this
treatment regimen in patients with resistant or refractory CD20-positive, non-Hodgkin’s
lymphoma.
2. Methods
The study was performed as a prospective, two-center, dose-escalation study of
ibritumomab tiuxetan, with dose escalation based on prospective patient-specific
organ dosimetry determined from 111 In ibritumomab tiuxetan imaging. The primary
operational goal of the study was to determine if precision, prospective, SPECT-CT organ
dosimetry-based outpatient myeloablative radioimmunotherapy, with autologous stem
cell transplantation (ASCT), in a two-center study was logistically feasible. The primary
clinical goal was to determine the non-hematopoietic MTD of 90Y ibritumomab tiuxetan,
with rituximab in vivo purging and ASCT support, using the precision dosing method.
The study was conducted according to the guidelines of the Declaration of Helsinki,
was approved by the IRBs of the two participating sites (IRB# NA_00036237), and written
informed consent was secured for all patients. The trial was initiated before the clinicaltrials.
gov (accessed on 5 June 2021) registration procedure was required.
Inclusion criteria: Eligible patients had relapsed or refractory CD20-positive low-grade,
mantle cell, or diffuse large-cell NHL, rituximab sensitivity (rituximab-sensitive defined
as at least partial response to rituximab or rituximab-containing regimen and response
duration of at least 6 months), and age > 18 years. In addition, patients had to have
acceptable function of bone marrow (platelet count ≥ 75,000/mm3 , WBC ≥ 3000/mm3 ,
lymphomatous marrow involvement < 35%), and adequate liver, heart, and kidney function
(creatinine ≤ 2 mg/dL, direct bilirubin ≤ 2 mg/dL, LVEF ≥ 45%, DLCO > 50%). Patients
had to have an anatomically measurable tumor.
Theranostic regimen: In the first phase of the theranostic regimen, rituximab
(375 mg/m2 ) was administered weekly for 4 consecutive weeks, followed by a single
dose of cyclophosphamide (2.5 g/m2 ). Filgrastim 10 mcg/kg was administered after cyclophosphamide until stem cell collection. Patients with successful stem cell collection (at
least 2 × 106 CD34 cells/kg) proceeded to RIT. In the second phase of the treatment, on Day
1, patients were given a dosimetric dose of 111 In ibritumomab tiuxetan (185 MBq), followed
by planar scans and blood sampling at 0–1, 4, 24, 72, and 144 h post-tracer injection and a
quantitative SPECT/CT at 24 h. Hybrid planar-SPECT quantification and MIRD dosimetry
with liver mass corrections were used to evaluate organ doses. On Day 15, 90 Y ibritumomab
tiuxetan was administered at a cohort-specific radiation-absorbed dose based on the results
of the organ dosimetry. Stem cell infusion occurred when estimated marrow dose rate was
<1 cGy/hour. Estimates of bone marrow radiation-absorbed dose were based on the most
conservative estimates of dose obtained from blood and image-based marrow dosimetry.
The study schema is shown in Figure 1. The theranostic procedures were performed at
two different physical sites, though dosimetry was calculated at a single site, Johns Hopkins
University School of Medicine. A total of 13 patients were treated with 90 Y ibritumomab
tiuxetan at Johns Hopkins University, Baltimore, MD, and 5 at the University of Wisconsin,
Madison, WI, USA.
A modified continual reassessment method (CRM) dose escalation was used to determine the target radiation-absorbed dose for each cohort. The CRM was initiated by
assuming a 10% response would occur from 10 Gy and a 90% response would occur from
35 Gy delivered to the liver. The probability of toxicity was assumed to follow a logistic
dose response model which was updated after each cohort. The initial cohort received the
standard 14.8 MBq/kg (0.4 mCi/kg) dose of 90 Y, irrespective of predicted organ dose. Dose
cohorts determined by this method were 14.8 MBq/kg and (maximum liver-absorbed dose
of 90 Y RIT) 14–18, 24, 28, and 30.5 Gy in Cohorts 1–5, respectively [20].
90 Y
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(21)
10 (42)
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# (%)
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Transformed
or
Mixed
Follicular
Lymfor each patient were calculated using a combination of planar whole-body images
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at five time points and two SPECT/CT images acquired at one time point. The imaging was
performed with a GE Millenium VG/Hawkeye SPECT/CT system with a 1.5875 cm thick
crystal at both performance sites. The whole-body images were acquired at, nominally, 0–2,
4, 24, 72, and 144 h post-infusion of 111 In ibritumomab tiuxetan. Images were acquired in
14% wide-energy windows centered on both 111 In photo-peaks and corrected for scatter
using the TEW method with a 152 keV ± 4% scatter window below the lower photo-peak
and a 205 keV ±10% scatter window between the two photo-peaks. A source with known
activity was included in the whole-body scan and used to adjust for sensitivity variations,
and planar images of the source were used to measure the system’s sensitivity for SPECT
image quantification. Whole-body images were scatter-corrected using the TEW method
(assuming no counts above the upper photo-peak), the geometric mean from opposing
views was calculated, and the resulting voxel values converted to activity using the counts
from the first time point and the assumption that all activity was retained in the body at the
first time point. Details and evaluation of the quantitative methods are provided in several
references [18,19,21,22]. SPECT/CT of the thorax and upper abdomen was performed
at 24 h post-injection and reconstructed using vendor supplied software that included
attenuation and TEW scatter corrections. These regions of the body were selected to allow
estimation of the activity distribution in the dosimetrically important organs, i.e., the lungs
and liver.
The predicted radiation-absorbed dose and the administered therapeutic dose for each
patient were calculated using the above images using hybrid SPECT/planar methodology [19,22]. Whole-organ volumes of interest (VOIs) were manually defined using both
the CT and SPECT images and quantified activity in the major organs. It was sometimes
difficult to determine which voxels belong to the liver due to the limited resolution of
the SPECT/CT images and high uptake at 24 h post-administration in the spleen and
heart. In this case, we included only voxels in the liver VOIs that were certain to represent
liver tissue. Projections of the SPECT organ VOIs were used to guide manual definition
of regions-of-interest in the planar geometric mean images. The whole-body geometric
mean images were quantified using the assumption that all the activity was present in the
0–2 h images and corrected for sensitivity variations using a VOI defined over the standard
source image. Time-activity curves were generated from the planar images, adjusted for
radioactive decay to represent 90 Y activity, fit with mono- or bi-exponentials, and rescaled
so that the activity for each organ was equal to the activity for that organ at the time of the
SPECT/CT acquisition. These curves were integrated and divided by the administered
111 In activity to give the residence time (time-integrated activity coefficients) for each organ.
Specific doses (radiation-absorbed dose per unit administered activity) were calculated
from the residence times using MIRD methodology, as implemented in the MIRDose 3.0
code. The appropriate gender for each patient was used. The liver dose was mass corrected,
as described above, based on the volume of the liver VOI, an assumed density of 1.0 g/cc
for the liver, and the standard organ mass for the appropriate gender. This method is
equivalent to using a VOI smaller than the full liver to estimate the activity concentration
in the liver and estimating the total liver activity from this activity concentration and the
liver volume based on the standard liver volume of the MIRD phantom. The accuracy
of this methodology has been validated in [23]. The target administered activity needed
to give the target dose was estimated by dividing the target liver dose for the cohort by
the specific liver activity, calculated as described above. Images, ROIs, VOIs, and dose
calculations from the remote performance site were reviewed centrally at Johns Hopkins.
All calculations were completed and reviewed with the PI, and the patient-specific
treatment dose was administered at approximately 15 days post-administration of the
planning dose. Representative whole-body images and SPECT/CT images with regions of
interests selected are shown in Figure 2, which illustrates the theranostic dosimetry schema.
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fusion of 250 mg/m2 rituximab is given over 1–2 h immediately prior to administration of
(Cardinal Health, Dublin, OH, USA). Given that the patients had received weekly infusions
of rituximab for each of the 4 weeks prior to the dosimetric dose, no unlabeled rituximab
was administered immediately prior to infusion of the dosimetric or the therapeutic doses.
This is in contrast to the FDA-approved clinical therapy approach, in which an infusion
of 250 mg/m2 rituximab is given over 1–2 h immediately prior to administration of each
of the dosimetric or therapeutic doses. In all cases, patients were treated as outpatients,
as their radiation emissions (bremsstrahlung), as assessed by measured radiation levels
at one meter following therapy, allowed for them to remain as outpatients in compliance
with state and NRC radiation safety guidelines. No post-treatment dosimetric imaging
was performed.

2.4. Stem Cell Reinfusion
Stem cells were reinfused on an outpatient basis when it was predicted that the
radiation-absorbed dose to the stem cells would be less than 1 cGy/h. This prediction was
based on the higher predictions made from marrow dosimetry calculations based on blood
draws and imaging. The blood-based dosimetry involved sequential measurements of
residual blood radioactivity following treatment (obtained on the days of imaging), and
the image-based dosimetry used the same methodology as for other organs but with VOIs
drawn on lumbar vertebrae and the pelvis. Conservative estimates were used so as to
minimize the possibility of radiation damage to the reinfused stem cells. The number of
stem cells infused varied based on the success of the stem cell mobilization and collection
steps with re-engraftment from 7 to 19 days post-reinfusion.
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2.5. Follow-Up
The RIT and the stem cell infusions were performed as outpatients; however, patients were closely followed for signs and symptoms of toxicity as they rapidly became
lymphopenic and neutropenic following higher doses of 90 Y anti-CD20. Patients were
managed by the marrow transplantation unit, and if neutropenic fevers or other side
effects developed that were not readily manageable as outpatients, patients were admitted
to the hospital for additional supportive therapy. Patients were followed regularly for
hematological and systemic toxicities, with a special emphasis on hepatic toxicity. Imaging
assessments, typically whole-body CT, were performed at 60 days post-90 Y RIT and also
at approximately 6-month intervals following treatment with response assessed by the
International Working Group criteria (IWG), unless there were clinical signs suggesting
earlier progression. The study was terminated early due to sale of the drug provider, meaning
that completion of the dose escalation, as well as long-term follow-up data are not available.
3. Results
3.1. Dosimetry
The prospective planar + SPECT/CT dosimetry methods were successfully performed
at a central dosimetry site in all 18 patients who mobilized their stem cells and who were
suitable for RIT. In all cases, the liver or spleen were the tissues that were predicted to
receive the highest radiation-absorbed dose from the therapy. However, splenic dose
was not considered dose-limiting as it was a potential site of tumor involvement. The
administered activity per unit mass required to deliver a uniform 10 Gy dose to the liver
was 26.8 ± 7.3 MBq/kg of 90 Y (range: 12.1–41.4 MBq/kg) of ibritumomab tiuxetan, indicating considerable heterogeneity among patients (Table 2, Figure 3a,b). The prospective
estimation of predicted therapeutic organ radiation-absorbed dose was optimized for the
lungs, liver, kidneys, and the heart. Organs not included in the two SPECT/CT fields-ofview could only be assessed for dosimetry by planar methods, but these organs were not
dose-limiting. As the focus of the study was not to estimate tumor radiation-absorbed
dose, tumor doses were not calculated. Organ dosimetry estimates and injected activity
levels and the target infused activity level are shown in Table 2. All patients were treated
as outpatients as radiation emission levels were low enough to comply with local and
NRC/state regulations, allowing for outpatient release following therapy.
Table 2. Injected radioactivity quantities and targeted major organ radiation doses from these activities. # = patient number.
Patient
Mass
Gender
(kg)
#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
mean
median
SD
min
max

M
F
M
M
F
M
M
F
F
M
F
F
F
M
F
M
M
M

Height
(cm)

92.3
59
101.3
76.5
59
77.6
63
71.1
69
82.5
68.5
86.7
70.2
68.8
95.4
85
90.7
81

175
165
175
179
150
176
170
159
145
178
160
160
157
177.8
160
184.2
173

77.6
77.1
12.5
59.0
101.3

167.3
170.0
11.2
145.0
184.2

Prescribed
AA
(GBq)

Actual
AA
(GBq)

Target
Liver AD
(cGy)

Liver
AD
(cGy)

Heart
AD
(cGy)

Lungs
AD
(cGy)

Kidneys
AD
(cGy)

Spleen
AD
(cGy)

MBq/kg for
10 Gy Liver
Dose

3.36
2.52
3.11
4.53
2.81
2.58
3.87
3.01
3.58
3.12
4.26
5.10
5.21
6.32
6.98

1.42
0.88
1.52
3.35
2.46
3.08
4.50
2.80
2.59
3.49
2.98
3.55
3.19
4.24
5.04
5.29
6.33
6.26

1800
1800
1800
2400
2400
2400
1800
1800
2400
2400
2400
2800
2800
2800
3050

1269
402
363
2112
1180
2053
2500
1348
2112
1672
1378
1678
1380
2261
2250
2848
2806
2734

261
276
74
1061
610
613
1440
642
787
897
2431
1123
879
1410
1072
1411
1635
1945

291
247
167
1155
563
652
1898
621
734
1020
918
1211
950
1327
1318
1911
2196
1946

301
249
171
1087
764
1132
1322
677
594
817
694
1133
898
1235
1129
845
948
1202

388
408
2647
1173
902
1054
1894
685
1109
1150
1073
2337
1177
2249
2017
1147
1520
2030

12.1
37.1
41.4
20.8
35.4
19.3
28.6
29.3
17.8
25.3
31.6
24.4
32.9
27.3
23.5
21.9
24.9
28.3

1796.8
1865.4
744.4
363.3
2847.7

1031.4
978.8
609.2
73.9
2430.6

1062.5
984.8
616.9
166.5
2196.4

844.3
871.6
347.4
170.7
1321.8

1386.7
1161.9
663.8
388.4
2647.2

26.8
26.3
7.3
12.1
41.4
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Figure 3. (a) Plot of activity per unit mass (MBq/kg) required to deliver 10 Gy to the liver using 90Y ibritumomab tiuxetan
Figure 3. (a) Plot of activity per unit mass (MBq/kg) required to deliver 10 Gy to the liver using 90 Y
by patient number. Note that there is an approximately 3.5-fold variability between the highest and lowest required activ90
ibritumomab
tiuxetanactivity
by patient
number.
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(b) Plot
of administered
activity to
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deliver 10 Gy to the liver vs. body mass. Note there is only a modest (r = 0.37) correlation between
Marrow Reconstitution
these values,3.2.
supporting
the need for patient-specific dosimetry beyond adjusting the dose for
Six
patients
did not adequately mobilize stem cells and could not be treated with 90Y
patient weight.
ibritumomab tiuxetan. In the 18 patients treated with 90Y, the days to engraftment postASCT were, for Cohort 1 (14.8 MBq/kg): 15 days median (range 11–19), Cohort 2 (14–18
Gy): 15.5 days median (range 14–18), Cohort 3 (24 Gy): 10.5 days median (range 10–14),
and Cohort 4 (28 Gy): 12 days, range 9–14. The time to engraftment did not appear to
depend on the radiation-absorbed dose but seemed somewhat related to the number of
infused stem cells
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3.2. Marrow Reconstitution
Six patients did not adequately mobilize stem cells and could not be treated with
ibritumomab tiuxetan. In the 18 patients treated with 90 Y, the days to engraftment
post-ASCT were, for Cohort 1 (14.8 MBq/kg): 15 days median (range 11–19), Cohort 2
(14–18 Gy): 15.5 days median (range 14–18), Cohort 3 (24 Gy): 10.5 days median (range
10–14), and Cohort 4 (28 Gy): 12 days, range 9–14. The time to engraftment did not appear
to depend on the radiation-absorbed dose but seemed somewhat related to the number of
infused stem cells.
90 Y

3.3. Toxicities
In the 18 patients who adequately mobilized stem cells, all patients engrafted successfully post-RIT. Notable Phase 1 (mobilization) Grade 3–4 toxicities included: leukopenia, neutropenia, thrombocytopenia, nausea/vomiting, febrile neutropenia, and elevated
creatinine. Notable Phase 2 (111 In Ibritumomab Tiuxetan, 90 Y ibritumomab tiuxetan,
ASCT) Grade 3–4 toxicities included leukopenia, neutropenia, thrombocytopenia, nausea/vomiting, febrile neutropenia, anemia, headache, myalgia, elevated creatinine, elevated AST, elevated ALT, infection with neutropenia, and diarrhea. No significant hepatotoxicity was observed, despite the liver generally receiving a higher absorbed dose
of radiation than any other organ. One patient had a rise in serum bilirubin in excess
of 3, but this was associated with tumor progression in the liver and porta hepatis. No
cardiopulmonary toxicity directly attributable to the therapy was seen, though one patient
died on day 27 with pneumonia.
Therapy was delivered in the outpatient setting. Six patients were hospitalized after
receiving 90 Y ibritumomab tiuxetan: four for febrile neutropenia. Admission was also
required in one patient for progressive disease and another for diarrhea. One patient died
from progressive disease (day 3 post-transplant), a second patient died of complications
due to pneumonia (day 27 post-transplant), while another patient died from progressive
disease > 12 months post-ASCT, and a fourth patient died from progressive disease but
never received Y2B8 or ASCT. One patient at the 18 Gy dose level developed myelodysplastic syndrome (MDS). One patient at 24 Gy developed Grade 2 auto-GVHD (graft vs.
host disease) localized to the mouth. Additional long-term follow-up of patients was
not available.
3.4. Therapeutic Response
Eighteen patients qualified for evaluation at sixty days post-transplant, thirteen patients achieved a CR, three had a PR, while two had PD. The frequency and duration of
response is shown in Table 3 by dose cohort. There was not an obvious trend to a higher
response rate nor longer PFS apparent across dose ranges (Table 3).
Table 3. Response rates and duration by dose cohort.
Cohort

Number of Patients

Median (Months)

Range (Months)

14.18 Mbq/Kg
14–19 Gy
24 Gy
28 Gy
30.5 Gy
Overall

3
5
6
3
1
18

12.6
9.0
9.3
23.0
>27
>13

6.1–18.4
0.1–9.7
0.9–40.2
9.0–>37
>27
0.1–40.2

4. Discussion
We demonstrated the feasibility of a prospective, precision, SPECT-CT + planar organ
dosimetry-based, dose escalation, outpatient myeloablative radioimmunotherapy with
autologous stem cell transplantation (ASCT) theranostic regimen in patients with extensively pre-treated non-Hodgkin’s lymphoma. This organ dosimetry method was feasible
in the short window of time following infusion of the 111 In ibritumomab tiuxetan, in a
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two-center study using a centralized, standardized dosimetry regimen using comparable
imaging equipment.
Six of the twenty-four patients entered in the study did not adequately mobilize stem
cells sufficiently to advance to transplant, thus eighteen patients received a therapeutic
dose of 90 Y ibritumomab tiuxetan. The pure beta energy emission of 90 Y and the limited
excretion of 90 Y from the body (approximately 5% urinary excretion) allowed this theranostic approach to be performed within the guidelines of applicable local radiation safety
rules without hospitalization for radiation safety considerations [15]. Four of the eighteen
patients treated with 90 Y in the study required hospitalization for complications after
treatment. A totally outpatient regimen was possible in 78% of the treated patients. This
outpatient approach is in contrast to the prior use of 131 I tositumomab at high administered
radioactivity doses or 131 I MIBG, where hospitalizations for radiation isolation are required
for days to weeks before patients can be discharged safely from the hospital [12,13].
The individualized dosimetry approach applied here allowed 90 Y ibritumomab tiuxetan to be delivered safely with relatively modest toxicity, other than that expected to the
bone marrow (which was reversed with stem cell transplant) in most cases. The maximum
activity administered, 6.33 GBq (171 mCi), was greater than 5 times the FDA-approved
maximum administered activity (32 mCi) for non-myeloablative treatment.
Notable is that the liver radiation-absorbed dose of 28 Gy in 4 patients was well
tolerated. This single dose of internally administered radiation to the liver in patients
without liver disease suggests the MTD lies above 28 Gy radio-antibody radiation delivery
to the liver. We presume the liver uptake of the radio-antibody is uniformly delivered to
the hepatocytes. These data build upon those reported by Cremonesi whose trial limited
planned Y-90 zevalin dose delivery to the liver to 20 Gy [16]. Our data also build upon
the results of Chiesa, whose highest radiation-absorbed dose to liver was 24.3 Gy, in a
patient receiving 45 MBq/kg of Y90 zevalin [17]. Knowledge that the MTD to the liver
from radio-antibodies labeled with Y90 exceeds 28 Gy expands our knowledge of liver
radiosensitivity to internally administered radio-pharmaceuticals. Using conventional
fractionated external beam irradiation, the maximum tolerated radiation-absorbed dose
to the liver is estimated as 30 Gy [24]. Standard fractionation is typically delivered as
200 cGy/day × 5 days/week [25]. The initial dose rate from Y90 ibritumomab tiuxetan is
likely somewhat higher than that of external beam irradiation due to the 64 h half-life of
Y90, but the lack of hepatic toxicity with Y90 suggests that the internally delivered radiation
is no more toxic than external beam radiation. While biologic effective dose (BED) is in
theory more relevant, it is very hard to confidently determine BED due to uncertainties in
underlying assumptions in the liver.
Dosimetry data to the liver from radiolabeled microspheres is difficult to directly
compare to the more uniform delivery of radio-antibodies to the hepatocytes. Since
microspheres are delivered intra-arterially and lodge in pre-capillary arterioles, they are
expected to have a non-uniform dose delivery to the liver, with more dose to tumor than
liver [20].
There have been multiple other studies in which 90 Y ibritumomab tiuxetan has been
combined at the standard dose of 14.8 MBq/kg with myeloablative chemotherapies and
stem cell transplant [25–27]. These do not provide information about the MTD of 90 Y
ibritumomab tiuxetan monotherapy at myeloablative radiation dosing but have generally
supported the safety of including standard dose ibritumomab tiuxetan RIT as part of a
myeloablative treatment regimen in NHL.
90 Y ibritumomab tiuxetan has been given at myeloablative doses as a single agent
on an inpatient basis. Ferruci et. al. performed a dose-escalation study in 13 patients
at the following dose levels, 29.6 MBq/kg (0.8 mci/kg), 44.4 MBq/kg (1.2 mCi/kg), and
55.5 MBq/kg (1.5 mCi/kg), expanded upon by Cremonesi [16,28]. Using the planar dosimetry approach, they also showed considerable variability in the predicted organ radiationabsorbed doses per unit activity administered. They also found that the greatest radiationabsorbed dose per unit activity was to the liver, with hepatic radiation-absorbed dose
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consistently exceeding that delivered to the lungs or the myocardium. While fairly large
administered radio-activities of 90 Y were administered, median liver radiation-absorbed
doses in the three dose cohorts were 7.2, 11.7, and 13 Gy, although these doses were not
prospectively determined. In one patient, an estimated liver dose of 23.4 to 31 Gy (depending on method) was reportedly delivered. Two patients developed febrile neutropenia,
one patient had HSV pneumonia, one patient had bacterial pneumonia, and one patient
had reactivation of hepatitis C with eventual death without evidence of residual tumor at
death. The authors concluded that the highest administered activity dose was appropriate
only for patients who had had 3 or fewer regimens of prior chemotherapy and whose
platelet counts were >150,000 mm3 . They suggested that the lower dose of 44.4 MBq/kg
(1.2 mCi/kg) was appropriate for patients who were more heavily pre-treated or whose
platelet counts were in the 100,000–150,000 range.
Given the considerable variability in organ dose reported by Ferruci et al., in two
instances, one at the highest planned dose (55.5 MBq/kg) and in one case at the middle
dose level (44.4 MBq/kg), the liver radiation-absorbed dose exceeded the upper limit
they planned to give. For example, at the 55.5 MBq/kg range, the authors predicted
liver radiation-absorbed doses of 7.9 to 31 Gy [27]. The variability in radiation-absorbed
dose to organs per unit administered activity they observed is consistent with the up to
3.5-fold variance we saw in our study in the radiation-absorbed dose per unit activity to
the liver/kg body weight using our hybrid SPECT/CT-planar method. We have previously
shown that this hybrid dosimetry approach is more accurate than conventional planar
methods [19,22], possibly accounting for some of the differences between the two reports
in absolute radiation-absorbed dose delivery. Cremonesi has pointed out the considerable
variability in radiation-absorbed dose estimation depending on the dosimetry approach
chosen for planar imaging. These differences are less in larger organs, however [16].
The determination of an MTD based on administered activity per unit body weight
is challenging if the radiation-absorbed dose delivered is highly variable as a function of
activity per unit mass. This is clearly the case with 90 Y ibritumomab tiuxetan. We targeted
delivery of up to 30.5 Gy to the liver without hepatic toxicity using organ-based dosimetry.
While only one patient was treated at this planned dose level, three were treated at the
28 Gy level and 6 at the 24 Gy level, and had no evidence of liver toxicity. Thus, the MTD
of 13 Gy to the liver proposed by Ferruci et al. is less than half of the dose we were able to
safely deliver in our study, and is well under the hepatic radiation-absorbed dose accepted
as the MTD for external beam radiation [24]. While the administered activity/weight-based
MTD that they propose may be sufficient to deal with the occasional patient with a high
hepatic radiation-absorbed dose, it appears to substantially underestimate the quantity
of radioactivity that could be delivered to the liver if accurate prospective dosimetry was
performed to guide the administered activity.
Devizzi et al. conducted a study in which chemotherapy was first given to NHL
patients, followed by administration of a 29.6 to 44.4 MBq/kg dose of 90 Y ibritumomab
tiuxetan, followed by stem cell transplant [29]. Toxicity was generally acceptable [29,30]. In
this study, planar dosimetry was performed. The liver was the organ receiving the highest
radiation-absorbed dose per unit activity (except for spleen), and in 4 patients treated at the
44.4 MBq/kg dose, a median liver radiation absorbed dose of 20.9 Gy with a range of 15.4
to 24.3 Gy was seen without hepatic toxicity. The authors predicted that they could have
given higher doses to the liver based on calculations of relative biological efficacy [17,29].
Our data support their view. It is difficult to compare other toxicities to our study in that
the patients studied by Devizzi had 6 cycles of chemotherapy before the RIT dose and a
tandem stem cell transplant procedure, and ours had only rituximab therapy.
We did not escalate the dose sufficiently to determine the MTD in our study. Unfortunately, due to a change in ownership of the company making the drug 90 Y ibritumomab tiuxetan, our study was terminated prematurely. Liver tolerance of these radiation-absorbed
doses was quite acceptable, suggesting room for further escalation of dose to the liver
before an MTD is achieved. Unlike the study by Ferruci, we had no challenges with en-
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graftment of stem cell reinfusions and cannot confirm that a low starting platelet count is a
contraindication to high-dose therapy if there are adequate numbers of stem cells infused.
Our entry criteria allowed patients with platelet counts of >75,000 mm3 and higher to enter
the study, as well as patients who had up to 35% bone marrow involvement.
90 Y ibritumomab tiuxetan has been investigated as a stem cell transplant agent in
patients with multiple myeloma in combination with high-dose melphalan. Using 111 In
ibritumomab tiuxetan for dosimetry and cohorts with radiation-absorbed doses to the liver
of 10, 12, 14, 16, 18, and 20 Gy, a dose limit was identified in 3 patients, yielding a maximum
tolerated liver radiation-absorbed dose of 18 Gy for this treatment [31].
Our observations on dosimetry support the MTD of 90 Y ibritumomab given without
immediately preceding chemotherapy as being greater than 28 Gy to the liver. Our study
also showed considerable biological and dosimetric variability in the absorbed dose to the
liver and other tissues as a function of the activity per unit mass of ibritumomab tiuxetan
administered [29]. We believe our estimates to radiation-absorbed dose variability are more
reliable than those previously reported with only planar imaging. These point to the clear
advantage of patient-specific dosimetry to safely optimize dose escalation.
Winter et al. integrated a somewhat higher than standard dose ibritumomab tiuxetan
therapy with chemotherapy as part of a myeloablative transplant regimen [32]. They used
personalized dosimetry to integrate ibritumomab tiuxetan RIT into the high-dose BEAM
chemotherapy regimen for patients with relapsed or refractory CD20+ non-Hodgkin’s
lymphoma (NHL). Several dose cohorts were studied with up to 17 Gy to critical organs
allowed in the highest dose cohort. The therapeutic dose of 90 Y ibritumomab tiuxetan was
followed by high-dose BEAM and autologous transplantation. The authors found two doselimiting toxicities at the 17 Gy dose level, which made 15 Gy the recommended maximum
tolerated radiation-absorbed dose. These toxicities were a death at day 10 of pneumonia
with renal failure, while another patient at the 17 Gy dose developed septic pulmonary
emboli. The authors found that a weight-based strategy using 29.6 MBq/kg (0.8 mCi/kg)
would have resulted in a wide range of radiation-absorbed doses to the liver and other
tissues: nearly 25% of patient cases would have received 17 Gy or more, and many would
have received less than 10 Gy. They concluded that dosimetry is required to avoid toxicity
and undertreatment. One would expect the MTD of ibritumomab tiuxetan to be lower
when combined with chemotherapy than when given as a monotherapy. The toxicities
they observed were consistent with neutropenia, but were not hepatic in nature. Given the
small size of our study and the heterogeneous makeup of our patients, it is difficult to make
too many conclusions about response rate. However, our 88% response rate with 13 CR
and 3 PR out of the 18 patients receiving the therapeutic dose of 90 Y ibritumomab tiuxetan
compares favorably with the 61.5% response rate (6 CR, 2 PR) in the 13 patients treated
with high-dose ibritumomab tiuxetan monotherapy by Ferruci et al. [28]. Our response rate
also compares favorably with the somewhat lower response rates reported for the lower,
standard dose (11.1 to 14.8 MBq/kg) ibritumomab tiuxetan therapy of 40% to 60% [33].
We did not observe a clear difference in response or duration, based on the different dose
cohorts studied, so are unable to conclude if higher radiation-absorbed doses truly resulted
in superior anti-tumor activity. Concerning, however, was the relatively short duration
of many of the responses. This duration of response may be shorter than that which has
been reported by Gopal, Press, and colleagues using 131 I tositumomab high-dose therapy
of lymphoma [12,13]. With a median follow-up time of 42 months, the estimated overall
and progression-free survival rates were 68% and 42% respectively, which are possibly
longer than those seen in our group. It is possible that the differing beta particle energies
between 131 I and 90 Y could be contributing to this possible difference. It is also possible
that our patients’ substantial rituximab treatments before RIT reduced tumor targeting of
the 90 Y ibritumomab tiuxetan.
One patient in our study developed a myelodysplastic syndrome. This is a serious
toxicity outcome and is well-known to follow myeloablative transplants, regardless of the
method of myeloablation. Our observation is consistent with that of Guidetti et al., who
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evaluated the hematopoietic damage and incidence of secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/AML) in patients who received myeloablative doses of the radiolabeled antibody 90 Y ibritumomab tiuxetan. The occurrence of
sMDS/AML was investigated prospectively in 53 elderly patients with non-Hodgkin’s
lymphoma (NHL) who underwent an autograft after high-dose RIT (HD-RIT) myeloablative conditioning with Y-ibritumomab tiuxetan. The 5-year cumulative incidence of
sMDS/AML was 8.29% [30].
It is important to point out that our approach to ibritumomab tiuxetan therapy differed
from standard approaches in several ways: (1) the absolute radiation-absorbed dose given
was much higher, and (2) the patients received weekly injections of 375 mg/m2 rituximab
for 4 weeks preceding the radiolabeled antibody doses. The purpose of these infusions
in patients who were still judged to be rituximab-sensitive was to purge tumor cells from
the circulation before harvesting the stem cells for transplant. While this is a logical
approach to clear circulating tumor cells, the amount of unlabeled rituximab given in the
4 weeks preceding the RIT was substantially higher than that typically given prior to RIT,
which is 250 mg/m2 × 2. We did not infuse rituximab immediately prior to either of
the ibritumomab tiuxetan infusions as rituximab would remain present in the circulation
at the time of the RIT doses based on the typical half-life of rituximab [34]. We did not
measure rituximab levels at the time of radio-antibody infusion. It is known that very
high levels of rituximab may reduce the targeting of radiolabeled anti-CD20 antibodies
to tumor in animal models [35]. In addition, there is some suggestive data that rituximab
may have some paradoxical radioprotective effects, at least in vitro, which might reduce
the biological efficacy of the radiation delivery to tumor [36]. Other considerations include
the possibility that the range of the high-energy beta particle of 90 Y may be too long to
efficiently deposit energy into small tumor foci. These small foci might be better treated
with a less energetic beta particle such as that from 131 I or alternative radiotracers with
lower beta energies [37]. A potential limitation of our study is that our predicted radiation
dose to the liver is estimated from the ibritumomab tiuxetan imaging studies and not from
direct measurement of Y90 activity in the liver, though in general, 111 In antibodies are
reasonably accurate predictors of 90 Y antibody pharmacokinetics [38]. Since this was not a
phase II study nor did we reach the MTD of 90 Y ibritumomab tiuxetan, it was not possible
to make definitive conclusions on the therapeutic efficacy of high-dose 90 Y Ibritumomab
tiuxetan in humans, as we did not treat a patient cohort at the MTD, though the treatment
was clearly quite active.
5. Conclusions
Precision, prospective, SPECT-CT + planar organ dosimetry-based outpatient myeloablative radioimmunotherapy, with autologous stem cell transplantation (ASCT) with highdose 90 Y-RIT, was technically feasible with outpatient ASCT support in 18 patients with
chemotherapy refractory or resistant CD20-positive non-Hodgkin’s lymphoma in a twocenter radiation-absorbed dose-escalation study. There was patient-to-patient heterogeneity
in dosing to the liver of over 3.5-fold. This dosimetry-based approach allowed a substantial
increase in administered activity and radiation-absorbed dose as compared to standard
FDA-approved non-myeloablative dosing with manageable toxicity. Tumor response rates
of 88% were seen, with most responses complete, though responses were not particularly
durable. The MTD was not reached in this study despite delivery of a targeted 30.5 Gy
to the liver as the drug became unavailable. Additional dose escalation, informed by
patient-specific radiation dosimetry, to determine second organ toxicities in the setting of
stem cell transplant support are in order to determine the maximum anti-tumor effect of
this form of radioimmunotherapy in B cell lymphomas given at the MTD, with such data
broadly informing other treatment studies with radiopharmaceuticals.
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6. Key Points
Question: Can outpatient precision prospective SPECT/CT + planar organ dosimetry
of In-111 ibritumomab tiuxetan be performed and allow safe dose escalation of 90 Y Ibritumomab tiuxetan, at myeloablative doses, in non-Hodgkin lymphoma patients who then receive outpatient stem cell transplants? What is MTD to liver, and is there therapeutic activity?
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